Health
Immunotherapy combination shrinks rare angiosarcoma tumors in 25% of patients – News-Medical.Net
Researchers from SWOG Cancer Research Network, a cancer clinical trials group funded by the National Cancer Institute’s Division of Cancer Diagnosis and Treatment,…
Reviewed by Emily Henderson, B.Sc.Nov 15 2020
Researchers from SWOG Cancer Research Network, a cancer clinical trials group funded by the National Cancer Institute’s (NCI) Division of Cancer Diagnosis and Treatment (DCTD), part of the National Institutes of Health, have shown that the immunotherapy combination of ipilimumab and nivolumab shrinks rare angiosarcoma tumors in 25 percent of all patients, with some having an even stronger response to the drug combination.
Results of the SWOG study, led…
-
General24 hours agoNew US tariffs on semiconductors coming ‘over the next week’, Donald Trump says
-
Noosa News24 hours agoPeter Dutton’s son ‘saving like mad’ to buy first home
-
General21 hours agoSearch for driver in Parramatta River after car hit woman before going into water
-
Business20 hours agoHow I’d invest in ASX 200 shares if I wanted to sleep well during market volatility